The role of the interleukin (IL)-6/IL-6 receptor axis in cancer

Mustafa Yassin Taher, David Marc Davies, John Maher*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

81 Citations (Scopus)


Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ‘trans-signal’ in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.

Original languageEnglish
Pages (from-to)1449-1462
Number of pages14
JournalBiochemical Society Transactions
Issue number6
Publication statusPublished - 22 Nov 2018


Dive into the research topics of 'The role of the interleukin (IL)-6/IL-6 receptor axis in cancer'. Together they form a unique fingerprint.

Cite this